EKF Diagnostics Holdings plc said it repurchased 60,000 ordinary shares at a weighted average price of 25 pence each on Tuesday, with all purchased shares to be cancelled.
The buybacks were executed in two tranches via the AIM exchange: 50,000 shares at 08:17:26 and 10,000 shares at 16:35:33, both at 25p per share. The company, headquartered in Penarth, Wales, confirmed the transactions will reduce its total issued share capital from 428,274,112 to 428,214,112 ordinary shares.
Following the cancellations, EKF Diagnostics will hold no treasury shares, and all remaining 428,214,112 ordinary shares will carry voting rights. The move aligns with the company’s capital management strategy, though no further rationale was disclosed.
EKF Diagnostics operates as a global diagnostics business specializing in point-of-care analyzers for hematology and diabetes, alongside life sciences services. The company maintains five manufacturing sites in the United States and Germany and distributes products to more than 120 countries.
